Top Ten most popular articles on Pharmafile.com this week
pharmafile | August 31, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â AstraZeneca, Eisai, Medicare, Novartis, UK, brexit, generics, king bio, pharma, top tenÂ
Eight months of 2018 down – where has the year gone? As we move from August into September, and a new issue of Pharmafocus becomes available, it’s been a eclectic week for news in the industry – from Novartis’ announcement that it will be expanding operations in the wake of the European approval of its CAR T therapy Kymriah, to the release of the UK Government’s less-than-reassuring “no deal” Brexit guidance. But the most popular story this week was the news that homeopathic medicines specialist King Bio have been forced to recall 32 of its children’s miedications due to a “microbial contamination”.
Read our the week’s ten most popular articles on Pharmafile.com now!
10. Generics could save US Medicare $1 billion per year
The United States national health insurance programme Medicare could have save $1 billion through the use of generic drugs according to a study published in the Journal of the American Medical Association.
9. Ionis/Akcea’s ultra-rare disease drug rejected by FDA
The FDA has opted to refuse approval to Akcea and Ionis’ Waylivra (volanesorsen) for the treatment of the ultra-rare hereditary condition familial chylomicronemia syndrome (FCS), despite the submission of Phase 3 data from the largest-ever study of the disease.
8. Drug slows brain shrinkage associated with progressive multiple sclerosis, study shows
The multiple sclerosis drug ibudilast, slowed brain shrinkages in patients with progressive MS, a study published in the New England Journal of Medicine has shown.
7. AstraZeneca’s once-weekly auto-injector Bydureon BCise wins EU approval in type 2 diabetes
AstraZeneca has announced that its auto-injector Bydureon BCise (exenatide 2mg prolonged-release suspension) has been approved by the European Commission for the treatment of type 2 diabetes, an expansion of the existing authorisation for Bydureon.
The British Government has published a document offering guidance as to what should be expected in the case of a no-deal Brexit.
5. Emergent snaps up Adapt and its opioid overdose therapy for $735m
Emergent BioSolutions has announced it has signed an agreement to acquire Adapt Pharma at a valuation of $735 million, a sum broken down into an up-front payment of $635 million and up to $100 million in milestone and royalty payments through to 2022.
4. Jazz Pharma’s acute myeloid leukaemia drug scores EU approval
Jazz Pharmaceuticals has revealed that its advanced liposomal formulation Vyxeos has received approval from the European Commission for the treatment of newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adult patients.
3. Eisai’s weight loss drug lorcaserin found safe in major study
Eisai’s weight loss drug lorcaserin does not increase people’s risk of major cardiovascular events according to a study of 12,000 overweight and obese patients.
2. Novartis to create 450 new jobs at Aargau site after Kymriah thumbs up
Swiss multinational Novartis is set to create up to 450 new jobs following the investment of 90 million Swiss Francs (£71 million) into the expansion of the company’s Stein site in the northern canton of Aargau over the next three years.
1. Homeopathic medicines specialist King Bio enacts nationwide recall
The Asheville-based drug maker King Bio is recalling 32 children’s medicines because of potential ‘microbial contamination’.
Related Content
Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …
LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …
NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZeneca’s benralizumab (Fasenra) as …
